- ICH GCP
- Registro de ensayos clínicos de la UE
Últimos ensayos
EudraCT Number: 2004-001331-36 | Sponsor Protocol Number: EORTC 08021 - ILCP | Start Date: 2005-02-17 | |||||||||||
Sponsor Name: IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A randomized phase III study of follow-up with or without Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer. | |||||||||||||
Medical condition: Non small cell lung cancer, advanced. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004149-16 | Sponsor Protocol Number: H3E-ES-S085 | Start Date: 2005-02-16 | ||||||
Sponsor Name: Lilly S.A. | ||||||||
Full Title: Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer | ||||||||
Medical condition: Locally Advanced, non-Resectable or Metastatic Urothelial Cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: ES (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-002228-17 | Sponsor Protocol Number: 2-2004 | Start Date: 2005-02-16 | ||||||
Sponsor Name: Danderyds Sjukhus | ||||||||
Full Title: Blödningsmönster och klinisk uppföljning av kvinnor som genomgått medicinsk abort och som har fått Implanon insatt i samband med aborten eller vid den första menstruationen efter aborten. | ||||||||
Medical condition: Blödningsmönster och klinisk uppföljning av kvinnor som genomgått medicinsk abort och har fått Implanon insatt i samband med aborten eller vid den första menstruationen efter aborten. | ||||||||
|
||||||||
Population Age: Adults | Gender: Female | |||||||
Trial protocol: SE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004592-11 | Sponsor Protocol Number: IGN101/2-02 | Start Date: 2005-02-16 | |||||||||||
Sponsor Name: IGENEON | |||||||||||||
Full Title: Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC) | |||||||||||||
Medical condition: Non-small-cell-lung-cancer stages IB, II A/B, III A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002795-42 | Sponsor Protocol Number: C04-002 | Start Date: 2005-02-16 | |||||||||||
Sponsor Name: ALEXION PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study | |||||||||||||
Medical condition: paroxysmal nocturnal hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000020-32 | Sponsor Protocol Number: CV131-176 | Start Date: 2005-02-16 | ||||||
Sponsor Name: Bristol Myers Squibb International Corporation | ||||||||
Full Title: The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension | ||||||||
Medical condition: Severe Hypertension | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: BE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-001491-39 | Sponsor Protocol Number: 03-0-192 | Start Date: 2005-02-16 | |||||||||||
Sponsor Name: Astellas Pharma US, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA | |||||||||||||
Medical condition: Invasive candidiasis or candidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) BE (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001054-84 | Sponsor Protocol Number: 2004/W/GI/02 | Start Date: 2005-02-16 | ||||||
Sponsor Name: NHS Lothian- University Hospitals Division | ||||||||
Full Title: A comparison of the efficacy of dietary hydroxypropylcellulose and questran as therapeutic agents in bile acid induced diarrhoea | ||||||||
Medical condition: these patients will have bile acid induced diarrhoea identified by an increased serum 7a-OH-cholestenone. and will have a history of one of 1. ileal resection 2. idiopathic bile acid diarrhoea.3. ... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-001854-10 | Sponsor Protocol Number: BO18039 | Start Date: 2005-02-16 | ||||||
Sponsor Name: F. Hoffmann-La Roche Ltd | ||||||||
Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in... | ||||||||
Medical condition: Metastatic Bone Pain | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | ||||||||
Trial results: View results |
EudraCT Number: 2004-002453-31 | Sponsor Protocol Number: AC-054-201 | Start Date: 2005-02-15 | ||||||
Sponsor Name: Actelion Pharmaceuticals Ltd. | ||||||||
Full Title: A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hem... | ||||||||
Medical condition: Prevention of ischaemic complications related to vasospasm in patients with aneurysmal subarachnoid haemorrhage | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: AT (Completed) SE (Completed) FI (Completed) DE (Completed) IT (Completed) BE (Completed) | ||||||||
Trial results: View results |